This review highlights recently discovered antimalarial natural products from marine and freshwater sources described in the literature from 2006 to 2008. The structures as well as bioactivities of compounds against the malaria parasites such as Plasmodium falciparum are discussed, including for example agelasine, xestoquinone, alisiaquinone, crambescidin, venturamide, dragomabin, gragonamide, viridamide, salinosporamide, chaetoxanthone, nodulisporacid, tumonoic acid, girolline, oroidin, nostocarboline, aerucyclamide and microcylamide 7806 and its revised structure.
Introduction
Malaria constitutes the most threatening parasitic infection in humans. Each year, between 300 to 500 million new clinical cases are reported by the world health organization, 1 resulting in annual deaths of about one million people, 2 of which threequarters of the fatalities are children below 5 years of age. 3 The most exposed continent is Africa, but also South-east Asia, Oceania, and Central and South America are under severe threat. Among the most affected countries are developing nations, which suffer from a weakly developed health care system.
There are four species of Plasmodium infecting humans: P. falciparum, P. vivax, P.
ovale and P. malariae, but most of the malaria cases are caused by the protozoan parasite P. falciparum. 4 The parasite is transmitted by Anopheles mosquitos, and therefore malaria can be controlled to some extent by conventional prevention strategies such as mosquito repellents, mosquito traps, insecticides or biological control. The introduction of efficient vaccines is still problematic, despite recent progress in this area. 5 As a direct consequence, the treatment of choice remains parasite chemotherapy with small molecule drugs both of natural origin or synthetics. 6, 7 In parallel, resistance of the malaria parasite to commonly used drugs such as quinine, chloroquine and mefloquine is emerging, 8 which results is an urgent need to develop new drugs against this disease. Also, an additional option for treatment, which implies reduction of the risk of resistance, offers the combination of two antimalarial drugs. Examples of such drug combinations are the artemisininamodiaquine and the artemether-lumefantine combination (Coartem).
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Antiplasmodial Agents of Marine and Freshwater Origin
The marine environment, taking more than 70% of the Earth's surface, is a rich source of both biological and chemical diversity. As a consequence, such aqueous environments harbor new compounds with great potential as pharmaceuticals, nutritional supplements, cosmetics and agrochemicals. 10 Many life forms in the marine environment such as algae, sponges, corals, ascidians and fungi have been investigated for their natural product content. [11] [12] [13] Many structurally and pharmacologically important substances have been isolated with novel antimicrobial, antitumor, anti-inflammatory, antimalarial, antibiotic or antifouling properties, and they are described in several excellent reviews that have appeared in recent years. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] In the current review, we give an overview of the bioactive metabolites recently isolated from marine organisms that have shown antiplasmodial activity and discuss their pharmacological potential. In addition, since some freshwater organisms have been found to populate both freshwater and marine environments (e.g. cyanobacteria), are found in brackish mixed environments, or are washed out into the ocean by rivers and streams, we have chosen to include examples from both aquatic domains.
While we do not claim completeness, research efforts published between 2006 and 2008 are discussed in the following chapters.
Several alkaloids were identified from marine sources in the last years. A survey of different invertebrates was conducted by Mendiola et al., 25 in order to classify these sources for antiplasmodial activity. Seven extracts from different marine species, three species of Chordata, two species of Echinodermata, one species of Cnidaria and one species of Porifera, collected on the northwest Cuban coast from Havana to Puerto Esperanza were reported to display moderate antimalarial activity. 25 Among them, three ascidians produced in vitro IC 50 values lower than 30µg/ml, and in vivo, the crude extracts caused partial reduction of Plasmodium berghei parasitaemia in mice. 25 Alkaloids and polyketides were found to be the major substances with antimalarial activity isolated from chordata, but the studied aqueous extracts of three ascidians were mixtures of compounds.
Although agelasidae sponges have been widely investigated, they still represent a source of new marine metabolites. 10 Three new diterpene alkaloids, agelasine J (1), agelasine K (2), and agelasine L (3), were recently isolated from the marine sponge From a Mycophora sp. Sponge, crambescidin 800 (4) was isolated, 27 which had been previously reported, 28 and few analogues had been prepared. Crambescidin 800 (4) showed in vitro activity against chloroquine(CQ)-resistant FCR3 P. falciparum (IC 50 = 240 nM) and CQ-sensitive 3D7 strains, (IC 50 = 160 nM). The most active analogue 5 had in vitro activity against P. falciparum strain 3D7 comparable to quinine as well, but slightly less than that of crambescidin 800 (IC 50 = 490 nM). 27 The mode of action has not been investigated, but similar compounds have been shown to be channel blockers or ATPase inhibitors. 27 Novel isoaaptamine analogues 29 were prepared by coupling acyl halides to the C9 position of isoaaptamine (6) 34 This mechanism is identical to the one observed for triclosan towards FabI of various species. 35, 36 Oroidin base (9) was assayed for its in vitro inhibitory activity on multidrug resistant K1 strain of P.
falciparum and it exhibited an IC 50 value of 3.9 µg/mL in the whole cell parasite assays. Oroidin (9) is a condensation product of the imidazol portion, 3-amino-1-(2-aminoimidazoyl)-prop-1-ene (10), which has no effect on PfFabI, but has unspecific effect on the malaria parasite, and 4,5-dibromopyrrole-2-carboxylic acid 11, which is not toxic, but has limited antimalarial and PfFabI inhibition activities. A previous report 37 described oroidin (as TFA salt) to be inactive towards the D6 and W2 strains of P. falciparum, however, a more recent study reported a moderate antimalarial effect with an IC 50 = 1.2 µg/mL.
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Benoit-Vical and co-workers 39 evaluated the effects of a natural product girolline (12) and some of its synthetic analogues in vitro and in vivo against P. falciparum and P.
vinckei petteri, respectively. This 2-aminoimidazol derivative was originally isolated from a New-Caledonian sponge Cymbastela cantharella, 40 and this compound was demonstrated for its antitumor properties. [41] [42] [43] More recently the compound 12 has been also isolated from another species of the marine sponge Axinella brevistyla collected in western Japan. 44 The IC 50 value of girolline (12) on the CQ-resistant strain FcM29 was determined to be 130 nM, and with artemisinin or chloroquine the compound inhibited parasitic growth by 100%. Several synthetic analogues were shown to possess IC 50 values higher than 50 µM. Girolline (12) showed also very high activity in an in vivo Plasmodium vinckei petteri assays, and even although the compound displays some toxicity, 42 it might considered as a natural compound with very promising activity against malaria. 39 The mode of action of this compound is debated in the literature, and Benoit-Vical et al. suggest its mechanism to be related to the inhibition of protein synthesis. 39 Our group has recently isolated nostocarboline (13), an acetyl-and butyrylcholinesterase, and trypsin inhibitor from the cyanobacterium Nostoc 78-12A. [45] [46] [47] The compound itself inhibits Plasmodium with high selectivity in nanomolar concentrations, and additionally, dimerization of nostocarboline leads to very potent and selective antiplasmodial agents. 48 Nostocarboline (74) was synthesized starting from norharmane via chlorination at C-6 and methylation according to published procedures. 45, 46 Scheme 1. Preparation of nostocarboline (13) 6-Cl-norharmane was also the starting material for the synthesis of ten nostocarboline symmetrical homo-dimers of general formular 14. Alkenyl, alkynyl, aryl, biaryl and alkyl linkers of various lenghts were employed for the corresponding dimers, which were obtained in a two-step process and in good yields (60 -95%).
Nostocarboline (13) Dragomabin (35) showed good antimalarial activity (IC 50 = 6 µM) against chloroquine-resistant Plasmodium falciparum, whereas the nonaromatic analogue, dragonamide B (36) was inactive in this assay.
An investigation of a marine cyanobacterium Oscillatoria nigro-viridis from Panama
led to the isolation of two novel bioactive lipopeptides, viridamides A (37) and B (38) . 63 Viridamide A (37) was tested against a series of relevant tropical pathogens and cancer cell lines, and it displayed significant activity against the parasitic protozoan P. falciparum (IC 50 = 5.8 µM), but also displayed strong activity against
Trypanosoma cruzi and Leishmania mexicana.
The marine cyanobacterium Blennothrix cantharidosmum was a source for six new acyl proline derivatives, tumonoic acids D-I (39-44), plus the known tumonoic acid A and lyngbyastatins as the active metabolites. 64 The tumonoic acids were originally isolated from a Lyngbya majuscula / Schizothrix calcicola assemblage, as well as collection of L. majuscula, all collected in Guam, 65 but phylogenetic investigation using 16S rRNA suggests that these compounds could also originate from Lyngbya/Blennothrix assemblages. The new compounds were tested in an array of assays, but only tumonoic acid I (44) displayed antimalarial activity with an IC 50 = 2 µM, none of the other naturally occurring analogues showed any activity in this assay at a concentration of up to10 µg/mL. The target of these compounds is unknown. 64 In addition to these peptides, several amino acid derivatives were isolated and Previously described xestoquinone [72] [73] [74] [75] [76] [77] [78] [79] [80] (51) was re-isolated from the marine sponge Xestospongia collected in Vanuatu in South Pacific. 36 The selectivity of the protein kinase inhibitory activity of xestoquinone against a panel of P. falciparum protein kinases was evaluated. 81 Xestoquinone (51), the most potent and the most abundant Pfnek-1 82 inhibitor, showed a moderate in vitro antiplasmodial activity against a FCB1 P. falciparum strain (IC 50 = 3 µM) and exhibited a cytotoxic activity on MCF7 cells with an IC 50 value of 20 µM, but it only exhibited weak in vivo activity at 5 mg/kg in Plasmodium berghei NK65 infected mice and was toxic at higher doses.
Four new bioactive compounds, alisiaquinones A, B and C (52, 53 and 54) and alisaquinol (55), were isolated from a New Caledonian deep-water sponge. 83 Alisiaquinone A (52) was slightly less cytotoxic and had low selectivity index.
Alisoquinone C (54), bearing the taurine substituent, displayed a submicromolar activity on Plasmodium falciparum and a competitive selectivity index on the different plasmodial strains, especially on the chloroquine-resistant strain PfFcMC29.
For alisaquinones A (52) and C (54) also the in vivo activity was investigated, but they displayed a relatively high level of toxicity.
A new tetronic acid, nodulisporacid A (56), isolated from a marine-derived fungus Nodulisporium sp. CRIF1 exhibited moderate antiplasmodial activity. 85 This compound was identified as a truncated derivative of lowdenic acid 86 and a known tetramic acid, vermelhotin (59) , obtained from an unidentified fungus CRI247-01 (a member of the order Pleosporoles), 85 and was previously obtained as a single Eisomer from another unidentified fungus. 87 Both compounds 56 and 59 revealed spontaneous inter-conversion between E-and Z-isomers, forming an equilibrium E/Z mixture with the ratio of 1:1 for nodulisporacid A (56) and 1:2 for vermelholtin (59) .
Nodulisporacid A (56), the two synthetic derivatives (57 and 58), as well as vermelhotin (59) exhibited good antiplasmodial activity with IC 50 values between 1-10 µM, with the latter compound displaying moderate cytotoxicity. 85 Previously,
vermelhotin (59) was tested against fungi and bacteria, but it showed no antifungal and antibacterial activities. 87 Natural products are prime candidates for the synthesis of analogues, which might be more effective and less toxic than the parent natural products. A series of semisynthetic derivatives 88 of a remarkably simple 1,2-dioxane derivative, plakortin (60) was prepared. Plakortin (60) itself was isolated from the Caribbean sponge
Plakortis simplex, and together with its 9,10-dihydro analogue 61, and two other analogues 3-epiplakortin (62) and plakortide Q (63) display submicromolar activities in vitro against chloroquine-resistant strains of P. falciparum.
89-91
The authors 88 confirmed the crucial role of the endoperoxide functionality in the antimalarial activity of plakortin derivatives, since diol (64) Hamann et al. 95 reported the preparation and evaluation for activity against several infectious diseases, of twenty semisynthetic analogues of (S)-(+)-curcuphenol (68).
They were prepared in yields greater than 90% by esterification of (S) falciparum whole cells, providing evidence that the PfFab pathway may be the potential cellular target of these compounds. 98 Several carbohydrates or glycosylated structures were also reported in the literature.
Glycosides 74 and 77, showed moderate antiplasmodial activity (IC 50 = 67 and 80 µM), which could be somewhat increased in the triacetylated derivative 76 (IC 50 = 28 µM).
68
The same authors 68 A new antimalarial polyether type metabolite 82 was isolated from the marine microorganism Streptomyces sp. H668. 99 The antimalarial activity of 28 was evaluated against both the chloroquine-susceptible (D6) and chloroquine-resistant (W2) clones of P. falciparum. Compound showed in vitro antiprotozoal activity with IC 50 values ranging from 100 to 200 ng/mL without significant cytotoxicity to Vero cells. The polyether metabolite 82 is also rather specific to the parasite displaying no toxicity at 4.75 µg/mL.
Conclusion
The present review highlighted various efforts on antimalarial agents that have been documented over the last three years thus clearly demonstrating the high scientific activity of the field. Many new interesting lead structures have been discovered, and valuable structure/activity information has been gathered through total or semisynthesis. Some compounds are currently evaluated in the clinic, and it is hoped that more efficient marine natural products will join the fight against malaria in the future.
